Pivalde, went back several months and reread our posts regarding...

Pivalde, went back several months and reread our posts regarding the Stanford University groups and the fact that Dr. Stamler would have interest in their work and discoveries in PD. Obviously, we have all we can handle with our Phase 2 MSA trial at the present time. If our results prove to be a " slam dunk or home run", would you think that we will receive regulatory approvals without the need to do the ATH 434 Phase 3 Trial?! Wouldn't it then be possible to partner with the Scientist crews at Stanford, Vanderbuilt, and/or elsewhere to pursue further testing with ATH 434 for Parkinson's and other diseases and conditions. Speaking of that, I find myself frequently wondering and stressing about what our old friend, Dr. Masters, is up to lately with PBT2 for Alzheimer's and Antibiotic Resistance, perhaps with ATH 434, and any other new Alterity small molecule drugs that may have potential. I wonder if anyone from Alterity regularly keeps in touch with Dr Masters. I think he is connected in some fashion with a Chinese neuroscience biotech or pharma. company which might present a problem in terms of conflict of interest. Hope you are well. Take care. Barry H.